In-Depth Study on Programmed Cell Death 1 Ligand 1 - Pipeline Review, H2 2016
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted pipeline therapeutics.
The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics development and features dormant and discontinued projects.
To access full report with TOC, please visit Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
- The report reviews Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics and enlists all their major and minor projects
- The report assesses Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics
- The report reviews Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics and enlists all their major and minor projects
- The report assesses Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Abeome Corporation Alnylam Pharmaceuticals, Inc. AlphaMab Co., Ltd AstraZeneca Plc Aurigene Discovery Technologies Limited Avacta Group Plc BeiGene, Ltd. Bristol-Myers Squibb Company CBT Pharmaceuticals Inc CytomX Therapeutics, Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Genosco ImmunoCellular Therapeutics, Ltd. Immunocore Limited IO Biotech ApS Kadmon Corporation, LLC Kymab Limited MedImmune, LLC Merck KGaA Merus NV Novartis AG PsiOxus Therapeutics Limited Regeneron Pharmaceuticals Inc Shanghai Henlius Biotech Co., Ltd. Sorrento Therapeutics, Inc. Sutro Biopharma, Inc. Theravectys SA Tikcro Technologies, Ltd.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 18:53
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home